Compile Data Set for Download or QSAR
Report error Found 136 Enz. Inhib. hit(s) with all data for entry = 8474
TargetLysophosphatidic acid receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251697(US9464060, 33 | US10100018, Example 33)
Affinity DataIC50: 0.300nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251696(US9464060, 32 | US10100018, Example 32)
Affinity DataIC50: 0.400nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251697(US9464060, 33 | US10100018, Example 33)
Affinity DataIC50: 0.400nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251681(US9464060, 17 | US10100018, Example 17)
Affinity DataIC50: 0.400nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251680(US9464060, 16 | US10100018, Example 16)
Affinity DataIC50: 1nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251681(US9464060, 17 | US10100018, Example 17)
Affinity DataIC50: 1nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251682(US9464060, 18 | US10100018, Example 18)
Affinity DataIC50: 1nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251678(US9464060, 14 | US10100018, Example 14)
Affinity DataIC50: 2nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251682(US9464060, 18 | US10100018, Example 18)
Affinity DataIC50: 2nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251678(US9464060, 14 | US10100018, Example 14)
Affinity DataIC50: 2nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251696(US9464060, 32 | US10100018, Example 32)
Affinity DataIC50: 2nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251677(US9464060, 13 | US10100018, Example 13)
Affinity DataIC50: 3nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251729(US9464060, 65 | US10100018, Example 65)
Affinity DataIC50: 4nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251677(US9464060, 13 | US10100018, Example 13)
Affinity DataIC50: 4nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251695(US9464060, 31 | US10100018, Example 31)
Affinity DataIC50: 4nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251725(US9464060, 61 | US10100018, Example 61)
Affinity DataIC50: 4nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251695(US9464060, 31 | US10100018, Example 31)
Affinity DataIC50: 5nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251730(US9464060, 66 | US10100018, Example 66)
Affinity DataIC50: 5nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251731(US9464060, 67 | US10100018, Example 67)
Affinity DataIC50: 5nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251726(US9464060, 62 | US10100018, Example 62)
Affinity DataIC50: 5nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251729(US9464060, 65 | US10100018, Example 65)
Affinity DataIC50: 5nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251675(US9464060, 11 | US10100018, Example 11)
Affinity DataIC50: 6nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251723(US9464060, 59 | US10100018, Example 59)
Affinity DataIC50: 6nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251675(US9464060, 11 | US10100018, Example 11)
Affinity DataIC50: 6nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251688(US9464060, 24 | US10100018, Example 24)
Affinity DataIC50: 7nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251699(US9464060, 35 | US10100018, Example 35)
Affinity DataIC50: 7nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251728(US9464060, 64 | US10100018, Example 64)
Affinity DataIC50: 7nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251683(US9464060, 19 | US10100018, Example 19)
Affinity DataIC50: 7nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251727(US9464060, 63 | US10100018, Example 63)
Affinity DataIC50: 7nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251730(US9464060, 66 | US10100018, Example 66)
Affinity DataIC50: 7nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251731(US9464060, 67 | US10100018, Example 67)
Affinity DataIC50: 7nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251725(US9464060, 61 | US10100018, Example 61)
Affinity DataIC50: 8nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251733(US9464060, 69 | US10100018, Example 69)
Affinity DataIC50: 8nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251676(US9464060, 12 | US10100018, Example 12)
Affinity DataIC50: 9nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251683(US9464060, 19 | US10100018, Example 19)
Affinity DataIC50: 9nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251726(US9464060, 62 | US10100018, Example 62)
Affinity DataIC50: 9nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251728(US9464060, 64 | US10100018, Example 64)
Affinity DataIC50: 9nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251727(US9464060, 63 | US10100018, Example 63)
Affinity DataIC50: 10nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251732(US9464060, 68 | US10100018, Example 68)
Affinity DataIC50: 10nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251685(US9464060, 21 | US10100018, Example 21)
Affinity DataIC50: 11nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251703(US9464060, 39 | US10100018, Example 39)
Affinity DataIC50: 11nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251708(US9464060, 44 | US10100018, Example 44)
Affinity DataIC50: 11nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251711(US9464060, 47 | US10100018, Example 47)
Affinity DataIC50: 11nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251688(US9464060, 24 | US10100018, Example 24)
Affinity DataIC50: 11nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 5(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251694(US9464060, 30 | US10100018, Example 30)
Affinity DataIC50: 12nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251684(US9464060, 20 | US10100018, Example 20)
Affinity DataIC50: 12nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251694(US9464060, 30 | US10100018, Example 30)
Affinity DataIC50: 12nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251733(US9464060, 69 | US10100018, Example 69)
Affinity DataIC50: 12nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251732(US9464060, 68 | US10100018, Example 68)
Affinity DataIC50: 13nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetLysophosphatidic acid receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251689(US9464060, 25 | US10100018, Example 25)
Affinity DataIC50: 14nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L- ±-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

Displayed 1 to 50 (of 136 total ) | Next | Last >>
Jump to: